Granite Investment Advisors LLC Has $4.43 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

Share on StockTwits

Granite Investment Advisors LLC cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,057 shares of the medical instruments supplier’s stock after selling 129 shares during the quarter. Granite Investment Advisors LLC’s holdings in Becton, Dickinson and were worth $4,434,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of BDX. State Street Corp lifted its holdings in shares of Becton, Dickinson and by 0.3% during the first quarter. State Street Corp now owns 11,490,473 shares of the medical instruments supplier’s stock worth $2,640,166,000 after buying an additional 39,890 shares during the last quarter. APG Asset Management N.V. lifted its holdings in shares of Becton, Dickinson and by 212.1% during the first quarter. APG Asset Management N.V. now owns 283,535 shares of the medical instruments supplier’s stock worth $65,148,000 after buying an additional 192,700 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Becton, Dickinson and by 1.0% during the first quarter. Morgan Stanley now owns 5,901,391 shares of the medical instruments supplier’s stock worth $1,355,965,000 after buying an additional 55,633 shares during the last quarter. Schroder Investment Management Group lifted its holdings in shares of Becton, Dickinson and by 177.4% during the first quarter. Schroder Investment Management Group now owns 13,471 shares of the medical instruments supplier’s stock worth $3,202,000 after buying an additional 8,614 shares during the last quarter. Finally, Tudor Investment Corp Et Al acquired a new position in shares of Becton, Dickinson and in the first quarter valued at $587,000. Institutional investors own 84.18% of the company’s stock.

NYSE BDX traded up $1.98 during midday trading on Friday, hitting $236.99. The company had a trading volume of 1,055,055 shares, compared to its average volume of 1,931,858. The company has a market capitalization of $68.70 billion, a PE ratio of 85.25, a P/E/G ratio of 2.36 and a beta of 0.84. The company has a current ratio of 1.45, a quick ratio of 0.97 and a debt-to-equity ratio of 0.71. The firm has a 50-day moving average price of $233.68 and a 200-day moving average price of $247.53. Becton, Dickinson and Company has a twelve month low of $197.75 and a twelve month high of $286.72.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.04 by $0.16. Becton, Dickinson and had a return on equity of 14.19% and a net margin of 5.30%. The company had revenue of $3.86 billion during the quarter, compared to analysts’ expectations of $3.96 billion. During the same quarter in the previous year, the firm earned $3.08 EPS. Becton, Dickinson and’s revenue was down 11.4% on a year-over-year basis. On average, equities analysts anticipate that Becton, Dickinson and Company will post 9.9 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were given a dividend of $0.79 per share. The ex-dividend date was Tuesday, September 8th. This represents a $3.16 annualized dividend and a dividend yield of 1.33%. Becton, Dickinson and’s payout ratio is 27.05%.

BDX has been the subject of a number of recent research reports. UBS Group upped their target price on Becton, Dickinson and from $265.00 to $280.00 and gave the company a “neutral” rating in a research note on Monday, August 10th. TheStreet lowered Becton, Dickinson and from a “b” rating to a “c+” rating in a research note on Monday, September 21st. Morgan Stanley cut their target price on Becton, Dickinson and from $285.00 to $270.00 and set an “equal weight” rating for the company in a research note on Thursday, August 27th. Barclays upgraded Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $300.00 target price for the company in a research note on Thursday, July 9th. Finally, SVB Leerink upped their target price on Becton, Dickinson and from $262.00 to $277.00 and gave the company a “market perform” rating in a research note on Wednesday, July 15th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Becton, Dickinson and has an average rating of “Buy” and a consensus target price of $278.47.

About Becton, Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: Bear Market – How and Why They Occur

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply